Akebia Therapeutics, Inc. (AKBA)
Healthcare
Drug Manufacturers - Specialty & Generic
1.30 $
-2.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Akebia Therapeutics, Inc. (AKBA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.7% of the shares are freely tradable; institutional investors hold 42.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
42.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
4.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
268Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 6.97 | 18,693,296 | -3.2 | 03/31/2026 |
| Vanguard Group Inc | 5.97 | 16,016,448 | +3.0 | 12/31/2025 |
| State Street Corp | 4.33 | 11,614,006 | -15.1 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.16 | 11,166,710 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 2.41 | 6,452,252 | +2.8 | 03/31/2026 |
| The Goldman Sachs Group Inc | 1.34 | 3,602,827 | -23.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.95 | 7,912,283 | +0.0 | 04/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.51 | 6,725,744 | -0.6 | 05/31/2026 |
| iShares Russell 2000 ETF | 2.26 | 6,057,709 | +0.9 | 05/29/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.12 | 3,001,615 | +0.6 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.